Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Top Cited Papers
Open Access
- 31 July 2003
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 349 (5) , 446-456
- https://doi.org/10.1056/nejmoa022536
Abstract
Elevated calcium and phosphorus levels after therapy with injectable vitamin D for secondary hyperparathyroidism may accelerate vascular disease and hasten death in patients undergoing long-term hemodialysis. Paricalcitol, a new vitamin D analogue, appears to lessen the elevations in serum calcium and phosphorus levels, as compared with calcitriol, the standard form of injectable vitamin D.Keywords
This publication has 38 references indexed in Scilit:
- Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenonKidney International, 2002
- Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney International, 2002
- Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteinsKidney International, 2002
- Osteodystrophy in the millenniumKidney International, 1999
- Calcitriol Directly Sensitizes Renal Tubular Cells to ATP-Depletion- and Iron-Mediated AttackThe American Journal of Pathology, 1999
- Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2American Journal of Kidney Diseases, 1998
- Soft tissue calcification in pediatric patients with end-stage renal diseaseKidney International, 1990
- Effect of the Hemodialysis Prescription on Patient MorbidityNew England Journal of Medicine, 1981
- Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysisJAMA, 1981
- ARTERIAL CALCIFICATION AFTER VITAMIN-D THERAPY IN HYPERPHOSPHATÆMIC RENAL FAILUREThe Lancet, 1968